The antitumour efficacy of LGK974 was primarily tested in transgenic MMTV-WNT1 mice, where it was demonstrated to significantly inhibit tumour growth development [76] and is now under evaluation in a Phase I study of selected patients with different malignancies dependent on Wnt ligands, including TNBC, for whom no effective standard treatment is available. Here, WNT1 is linked to neoplasm.